1. Neoadjuvant nivolumab plus chemotherapy led to a longer event-free survival and higher percentage of patients with a pathological complete ...
1. Almost 30% of patients had an objective response rate, with roughly three-quarters experiencing a reduction in tumour size. 2. ...
Atezolizumab showed a benefit for disease-free survival in patients with stage II-IIIA NSCLC compared to best supportive treatment. Grade 3 ...
1. Atezolizumab showed a benefit for disease-free survival in patients with stage II-IIIA NSCLC compared to best supportive treatment. 2. ...
1. Hypofractionated image-guided radiotherapy was not superior to conventionally fractionated radiotherapy monotherapy for patients with stage II/III non-small cell lung ...
1. Median overall survival and progression-free survival were significantly improved with cemiplimab monotherapy compared to chemotherapy. 2. Patients treated with ...
1. Osimertinib demonstrated a significantly longer duration of progression-free survival compared to standard of care epidermal growth factor receptor (EGFR)-tyrosine ...
1. Progression free survival and overall survival was significantly increased in patients who received pembrolizumab vs. patients who received platinum-based ...
1. Patients with advanced EGFR-associated non-small-cell lung cancer treated with dacomitinib had increased progression-free survival as compared to those without ...
1. Brachytherapy following sublobar resection (BSR) had no significant association with local NSCLC recurrence compared to sublobar resection (SR) alone. ...
